EUCTR2009-011585-28-BEActive, not recruitingPhase 1
A randomised double-blind placebo-controlled phase IIa study of orally administered BGC20-0134 in patients with relapsing-remitting multiple sclerosis (RRMS)
Conditions
Trial Snapshot
- Phase
- Phase 1
- Status
- Active, not recruiting
- Sponsor
- BTG International Ltd
- Enrollment
- 184
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional clinical trial of medicinal product
Eligibility Criteria
- Sex
- All
Inclusion Criteria
- •Patients aged =18 with relapsing-remitting multiple sclerosis (EDSS score 0-5.5), with evidence of disease activity defined as at least one relapse or the presence of active MRI lesion/s consistent with MS during the year prior to inclusion
- •Patients who have refused to be treated with approved disease modifying therapies available for MS, for any reason and once the investigator has fully informed the patients about the related benefits and potential adverse events associated with such treatments. Also, patients for whom such treatments have proved to be intolerable.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 182
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 2
Exclusion Criteria
- •MS-related exclusion criteria:
- •MS relapse or systemic corticosteroids in the previous 1 month
- •Secondary progressive (SPMS), progressive relapsing (PRMS), or primary progressive MS (PPMS)
- •Treatment with other agents for MS within the previous 3 months (intertferon beta, glatiramer acetate, intravenous immunoglobulin or plasmapherese) or within the previous 12 months (other MS drugs)
- •Treatment with agents for the non-symptomatic treatment of MS within the previous 3 months
- •General exclusion criteria
- •Pregnant or breast feeding
- •Participation in a clinical study of an unlicensed drug in the previous 6 months
- •Has a clinically significant abnormal serum biochemistry, haematology or urine examination values within 14 days prior to the start of the study.
- •Has a 12-lead ECG with abnormal QTc interval within 14 days prior to the start of the study.
- •Presence of pacemakers or foreign metal objects in the body which would contraindicate an MRI scan, or renal impairment which would contraindicate gadolinium injection
- •Has any systemic disease, which can influence his/her safety and compliance, or the evaluation of disability.
- •Any finding on medical history or physical examination which would prevent the patient being able to fully comply with the requirements of the study.
- •Any finding on medical history or physical examination which would affect absorption of the study drug; e.g. metabolic disorders.
- •Serious concomitant medical conditions: e.g. HIV infection, Hepatitis B or C, uncontrolled diabetes, malignancy.
- •Current history of cancer, excluding localised non-melanoma skin cancer
- •Known allergies to the study drug, its constituents or gadolinium (MRI contrast).
- •Has suffered from major depression or any other psychiatric disorder
- •Incapability of giving informed legal consent
- •Co-worker, student, relative or spouse of the investigator
- •Patients unable to swallow oral medications
- •Previous participation in this study
Investigators
Similar Trials
Active, not recruiting
Not Applicable
A randomised double-blind placebo-controlled phase IIa study of orally administered BGC20-0134 in patients with relapsing-remitting multiple sclerosis (RRMS)relapsing-remitting multiple sclerosisMedDRA version: 9.1Level: LLTClassification code 10063399Term: Relapsing-remitting multiple sclerosisEUCTR2009-011585-28-FRBTG International Ltd166
Active, not recruiting
Not Applicable
A randomised double-blind placebo-controlled phase IIa study of orally administered BGC20-0134 in patients with relapsing-remitting multiple sclerosis (RRMS)Estudio fase IIa, aleatorizado, doble ciego, controlado con placebo, de BGC20-0134 administrado de forma oral en pacientes con esclerosis múltiple recurrente remitente (EMRR)?Esclerosis Múltiple Recurrente-RemitenteRelapsing Remitting Multiple SclerosisMedDRA version: 9.1Level: LLTClassification code 10063399Term: Relapsing-remitting multiple sclerosisEUCTR2009-011585-28-ESBTG International Ltd166
Active, not recruiting
Not Applicable
Early phase clinical trial to evaluate the effectiveness and safety of a new orally administered drug in patients with relapsing-remitting multiple sclerosisEUCTR2009-011585-28-DEBTG International Ltd184
Completed
Not Applicable
A randomized double-blind placebo-controlled phase 1 study regarding safety, tolerability and pharmacokinetics/-dynamics of escalating single intravenous doses of ADRECIZUMAB (HAM 8101) in healthy male subjects.severe bacterial infection.10004018SepsisNL-OMON43493Adrenomed AG24
Completed
Not Applicable
A randomized double-blind placebo-controlled phase I study on the safety, tolerability and pharmacokinetics/-dynamics of escalating single intravenous doses of ADRECIZUMAB (HAM8101) in healthy male subjects during experimental endotoxemia.SepsisNL-OMON43006Adrenomed AG24